Surface Oncology Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 62

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $64.6M

  • Investors
  • 1

Surface Oncology General Information

Description

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 50 Hampshire Street
  • 8th Floor
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Surface Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 08-Sep-2023 $64.6M 00000 000.00 Completed Generating Revenue
5. Secondary Transaction - Open Market 00000 Completed Generating Revenue
4. IPO 19-Apr-2018 00000 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC 11-Jan-2016 00000 00000 Completed Product Development
2. Early Stage VC (Series A) 21-Nov-2014 $35.1M $35.1M 000.00 Completed Product Development
1. Seed Round 01-Jan-2014 Completed Product Development
To view Surface Oncology’s complete valuation and funding history, request access »

Surface Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00 00 00 00.000
To view Surface Oncology’s complete cap table history, request access »

Surface Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces
Drug Discovery
Cambridge, MA
62 As of 2023
00000
000.00 0000-00-00
000000&0 00000

00000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000000000000
Gosselies, Belgium
000 As of 0000
00000
000000000 00000

00000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000 00000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Surface Oncology Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
iTeos Therapeutics Formerly VC-backed Gosselies, Belgium 000 00000 000000000 00000
Sutro Biopharma Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
aTyr Pharma Formerly VC-backed San Diego, CA 00 00000 00000000 00000
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA 000 00000 000000&0
You’re viewing 5 of 30 competitors. Get the full list »

Surface Oncology Patents

Surface Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240025987-A1 Use of anti-il-27 antibodies Pending 25-May-2022 0000000000
US-20240026001-A1 Use of anti-il-27 antibodies Pending 25-May-2022 00000000000
US-20230036592-A1 Methods of treating cancer with an anti-cd39 antibody and pembrolizumab Pending 03-Jun-2021 000000000 0
US-20220389115-A1 Methods of treating cancer with an anti-cd39 antibody Inactive 03-Jun-2021 000000000
US-20210238292-A1 Anti-ccr8 antibodies and uses thereof Active 06-Jan-2020 C07K16/2866 0
To view Surface Oncology’s complete patent history, request access »

Surface Oncology Board Members (17)

Name Representing Role Since
Armen Shanafelt Ph.D Lilly Ventures Board Member 000 0000
Daniel Lynch Surface Oncology Chairman & Board Member 000 0000
Elliott Sigal Ph.D New Enterprise Associates Board Member & Member of Nominating, Corporate Governance Committee 000 0000
You’re viewing 3 of 17 board members. Get the full list »

Surface Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Surface Oncology Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amgen Ventures Corporate Venture Capital Minority 000 0000 000000 0
Atlas Venture Venture Capital Minority 000 0000 000000 0
Eight Roads Corporate Venture Capital Minority 000 0000 000000 0
Elliott Sigal Angel (individual) Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Surface Oncology FAQs

  • When was Surface Oncology founded?

    Surface Oncology was founded in 2014.

  • Who is the founder of Surface Oncology?

    Arlene Sharpe is the founder of Surface Oncology.

  • Where is Surface Oncology headquartered?

    Surface Oncology is headquartered in Cambridge, MA.

  • What is the size of Surface Oncology?

    Surface Oncology has 62 total employees.

  • What industry is Surface Oncology in?

    Surface Oncology’s primary industry is Drug Discovery.

  • Is Surface Oncology a private or public company?

    Surface Oncology is a Private company.

  • What is the current valuation of Surface Oncology?

    The current valuation of Surface Oncology is 000.00.

  • What is Surface Oncology’s current revenue?

    The current revenue for Surface Oncology is 000000.

  • How much funding has Surface Oncology raised over time?

    Surface Oncology has raised $313M.

  • Who are Surface Oncology’s investors?

    Amgen Ventures, Atlas Venture, Eight Roads, Elliott Sigal, and F-Prime Capital are 5 of 7 investors who have invested in Surface Oncology.

  • Who are Surface Oncology’s competitors?

    iTeos Therapeutics, Sutro Biopharma, aTyr Pharma, Corvus Pharmaceuticals, and Agios Pharmaceuticals are some of the 30 competitors of Surface Oncology.

  • When was Surface Oncology acquired?

    Surface Oncology was acquired on 08-Sep-2023.

  • Who acquired Surface Oncology?

    Surface Oncology was acquired by Coherus Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »